Form 4: Nektar Therapeutics CEO Sells Shares to Cover Tax Obligations

Nektar Therapeutics CEO Howard W. Robin sold 23,208 shares of common stock on May 19, 2025, to cover tax withholding obligations related to vesting RSUs.

Summary

• On May 19, 2025, Howard W. Robin, the President and CEO of Nektar Therapeutics, sold 23,208 shares of Nektar Therapeutics common stock.
• The sale was executed to cover required tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $0.67, with individual transactions ranging from $0.66 to $0.69.
• Following the transaction, Robin directly owns 1,063,693 shares of Nektar Therapeutics common stock and indirectly owns 410 shares via a spouse.

Sentiment

Score: 5

Explanation: This is a routine transaction related to tax obligations, so the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of insider trading activity and are required by the SEC to provide transparency into the transactions of company executives and directors. This particular filing relates to the sale of shares to cover tax obligations, which is a common practice.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is a common practice to cover tax obligations.

Key Dates

Keywords

Nektar Therapeutics, Howard W. Robin, stock sale, Form 4, tax withholding, RSUs, NKTR